Risk of Long-Term Clozapine Medication over Decades for Cardiac Adverse Events Including Heart Failure and Its Pathophysiology: A Japan and China Retrospective Cohort Analysis
Risiko einer Langzeit-Clozapin-Medikation über Jahrzehnte für kardiale unerwünschte Ereignisse einschließlich Herzinsuffizienz und ihre Pathophysiologie: retrospektive Kohortenanalyse aus Japan und China
Medical Sciences · 11.06.2026 · 14 (2) · 306
DOI: 10.3390/medsci14020306 ↗Auf einen Blick
Bei 315 Patient:innen mit Schizophrenie unter Clozapin war die altersstandardisierte Prävalenz von Herzinsuffizienz höher als in der Allgemeinbevölkerung. Als Risikofaktoren wurden längere Exposition, höhere Clozapin-Plasmaspiegel und mehr Monozyten genannt.
Fragestellung
Wie hoch ist das Risiko einer clozapinassoziierten Kardiotoxizität bei Langzeitmedikation, und welche Faktoren sind damit verbunden?
Methode
Multizentrische retrospektive Kohortenstudie mit Patient:innen aus Japan und China unter Clozapin-Monotherapie; Auswertung von NT-proBNP, LVEF und Blutuntersuchungen als unabhängige Variablen.
Ergebnisse
315 Fälle: 99 japanische und 216 chinesische Patient:innen. Herzinsuffizienz-Prävalenz gegenüber der Allgemeinbevölkerung höher; OR 3,2 (95 %-KI 1,4–6,4) in Japan und OR 6,9 (95 %-KI 3,6–12,0) in China.
Schlussfolgerung der Autor:innen
Die Studie zeigte eine asymptomatische Herzinsuffizienz als dritte kardiale Nebenwirkung von Clozapin, die Jahre später auftritt. Regelmäßiges NT-proBNP-Monitoring könne zur Verbesserung der Langzeitprognose beitragen.
Kernaussagen
- Herzinsuffizienz unter Clozapin häufiger als in der Allgemeinbevölkerung
- Risikofaktoren: längere Exposition, höhere Clozapin-Spiegel, mehr Monozyten
- >70 % der Fälle mit Stadium-B-Herzinsuffizienz ohne metabolische Komplikationen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Multizentrische Studie in der Zeitschrift Medical Sciences, online erschienen am 11.06.2026. Verfasst von Ruri Okubo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan. Hauptthemen laut MEDLINE: Clozapine, Heart Failure, Antipsychotic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Major Project of the Department of Science and Technology of Liaoning Province, Department of Science and Technology of Liaoning Province.
Themen: Patientensicherheit, Herzinsuffizienz
Abstract (Originalsprache)
Background/Objectives: Clozapine is the sole antipsychotic approved for treatment-resistant schizophrenia, but it is a double-edged therapeutic option due to various lethal adverse reactions. This study aimed to assess the risk of long-term clozapine medication-induced cardiotoxicity, which has not yet been fully elucidated.
Methods
This study is a multicenter retrospective cohort study of patients with schizophrenia in Japan and China who received clozapine monotherapy. Cases for which serum NT-proBNP concentration and LVEF derived from echocardiography were available in 2025 were included. In addition, blood examinations, including those administered by the Japanese Clozaril Patient Monitoring Service, were statistically analyzed as independent variables.
Results
Among a total of 315 cases, including 99 Japanese (clozapine exposure duration: 57.5 ± 4.0 months) and 216 Chinese (208.1 ± 11.0 months) cases, were enrolled. In both Japan and China, age-standardized prevalence of heart failure among patients with prescribed clozapine were higher compared to general population, with odds ratios of 3.2 (95%CI: 1.4–6.4) and 6.9 (95%CI: 3.6–12.0), respectively. The risk factors for stage-B heart failure associated with clozapine were prolonged exposure duration, higher plasma levels of clozapine, and increasing monocytes. Unexpectedly, over 70% of cases with stage-B heart failure associated with clozapine identified in this study did not have metabolic complications. Other than those with cardiomyopathy, myocardial infarction, ileus, or chronic renal failure, no cases with ejection fraction < 50% were observed, suggesting that stage-B heart failure associated with clozapine is speculated to be likely suggestive of HFpEF.
Conclusions
Traditionally, psychiatry has focused on myocarditis and cardiomyopathy developing several weeks and months after initiation of clozapine medication; however, this study revealed asymptomatic heart failure as a third cardiac adverse reaction of clozapine that develops years later. Therefore, regular monitoring of NT-proBNP contributes to improving long-term prognosis of treatment-resistant schizophrenia with prescribed clozapine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan.
- Department of Psychiatry, National Hospital Organization Sakakibara Hospital, 777 Sakakibara, Tsu 514-1292, Japan.
- Department of Psychiatry, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
- Department of Cardiology and Nephrology, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan.
- Jinzhou Kangning Hospital, Jinzhou 121019, China.
- Shenyang Jing'an Mental Health Hospital, Shenyang 110163, China.
ORCID-Profile: Tetsuji Kitano, Eishi Motomura, Kaoru Dohi, Motohiro Okada
Förderung
- Japan Society for the Promotion of Science
- Major Project of the Department of Science and Technology of Liaoning Province
- Department of Science and Technology of Liaoning Province
Zitieren
APA
Okubo, R., Yamamoto, N., Shao, X., Omori, T., Xiong, J., Liu, C., Kato, R., Murata, M., Kitano, T., Ito, Y., Oka, T., Onitsuka, T., Motomura, E., Dohi, K., Zhu, G., & Okada, M. (2026). Risk of Long-Term Clozapine Medication over Decades for Cardiac Adverse Events Including Heart Failure and Its Pathophysiology: A Japan and China Retrospective Cohort Analysis. Medical Sciences, 14(2), 306. https://doi.org/10.3390/medsci14020306
Vancouver
Okubo R, Yamamoto N, Shao X, Omori T, Xiong J, Liu C, et al. Risk of Long-Term Clozapine Medication over Decades for Cardiac Adverse Events Including Heart Failure and Its Pathophysiology: A Japan and China Retrospective Cohort Analysis. Medical Sciences. 2026;14(2):306. doi:10.3390/medsci14020306
BibTeX
@article{Okubo2026,
author = {Okubo, Ruri and Yamamoto, Nobutomo and Shao, Xiaojun and Omori, Taku and Xiong, Jian and Liu, Changhui and Kato, Ryo and Murata, Masahiko and Kitano, Tetsuji and Ito, Yuki and Oka, Tomoka and Onitsuka, Toshiaki and Motomura, Eishi and Dohi, Kaoru and Zhu, Gang and Okada, Motohiro},
title = {Risk of Long-Term Clozapine Medication over Decades for Cardiac Adverse Events Including Heart Failure and Its Pathophysiology: A Japan and China Retrospective Cohort Analysis},
journal = {Medical Sciences},
year = {2026},
volume = {14},
number = {2},
pages = {306},
doi = {10.3390/medsci14020306}
}
EUVIMED